Echo45 Advisors LLC Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Echo45 Advisors LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 573 shares of the medical research company’s stock after acquiring an additional 33 shares during the period. Echo45 Advisors LLC’s holdings in Thermo Fisher Scientific were worth $305,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of TMO. Evergreen Capital Management LLC boosted its stake in Thermo Fisher Scientific by 8.0% during the second quarter. Evergreen Capital Management LLC now owns 2,965 shares of the medical research company’s stock valued at $1,641,000 after buying an additional 219 shares during the last quarter. Sfmg LLC grew its holdings in shares of Thermo Fisher Scientific by 3.6% in the second quarter. Sfmg LLC now owns 6,049 shares of the medical research company’s stock valued at $3,345,000 after purchasing an additional 213 shares in the last quarter. Insigneo Advisory Services LLC raised its stake in Thermo Fisher Scientific by 6.4% during the second quarter. Insigneo Advisory Services LLC now owns 3,345 shares of the medical research company’s stock valued at $2,000,000 after purchasing an additional 200 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Thermo Fisher Scientific by 743.6% during the second quarter. Point72 Asset Management L.P. now owns 336,537 shares of the medical research company’s stock valued at $186,105,000 after purchasing an additional 296,646 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI increased its holdings in shares of Thermo Fisher Scientific by 1.9% in the 2nd quarter. Zurich Insurance Group Ltd FI now owns 220,314 shares of the medical research company’s stock worth $121,834,000 after buying an additional 4,115 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. This trade represents a 13.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,150 shares of company stock valued at $25,954,465. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

TMO opened at $574.72 on Thursday. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The business’s fifty day simple moving average is $530.86 and its 200-day simple moving average is $568.96. The company has a market capitalization of $219.83 billion, a price-to-earnings ratio of 36.03, a PEG ratio of 3.81 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the previous year, the business posted $5.69 EPS. The company’s quarterly revenue was up .2% compared to the same quarter last year. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share buyback program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were issued a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Analysts Set New Price Targets

TMO has been the subject of several recent research reports. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Stephens initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price on the stock. Finally, Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $648.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.